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ABSTRACT
Epigenetic silencing mediated by CpG methylation is a common feature of 
many cancers. Characterizing aberrant DNA methylation changes associated with 
tumor progression may identify potential prognostic markers for prostate cancer 
(PCa). We treated two PCa cell lines, 22Rv1 and DU-145 with the demethylating 
agent 5-Aza 2’–deoxycitidine (DAC) and global methylation status was analyzed by 
performing methylation-sensitive restriction enzyme based differential methylation 
hybridization strategy followed by genome-wide CpG methylation array profiling. In 
addition, we examined gene expression changes using a custom microarray. Gene Set 
Enrichment Analysis (GSEA) identified the most significantly dysregulated pathways. 
In addition, we assessed methylation status of candidate genes that showed reduced 
CpG methylation and increased gene expression after DAC treatment, in Gleason score 
(GS) 8 vs. GS6 patients using three independent cohorts of patients; the publically 
available The Cancer Genome Atlas (TCGA) dataset, and two separate patient 
cohorts. Our analysis, by integrating methylation and gene expression in PCa cell 
lines, combined with patient tumor data, identified novel potential biomarkers for PCa 
patients. These markers may help elucidate the pathogenesis of PCa and represent 
potential prognostic markers for PCa patients. 
INTRODUCTION
Prostate cancer (PCa) is the most common urological 
malignancy in western countries. The American Cancer 
Society estimates that 233,000 American men will be 
diagnosed with PCa in 2014 [1]. In recent years, prostate 
specific antigen (PSA) testing has led to a sharp increase 
in PCa incidence [2], yet serum PSA does not accurately 
measure the threat that PCa poses to the patient’s life [3]. 
It is estimated that approximately 15-30% of patients who 
undergo radical prostatectomy have been over-treated 
as the tumors would likely not affect their life span or 
quality of life [4], thus suffering the harsh side effects of 
this treatment without any clinical benefit. Tumors with 
the same histopathologic grade are biologically diverse, 
as some may remain indolent while others behave 
aggressively, leading to local recurrence and metastatic 
disease. Based on the vast tumor heterogeneity in PCa, 
more accurate biomarkers are needed to help accurately 
distinguish between indolent and aggressive PCas. A 
better understanding of the molecular mechanisms of PCa 
progression would help address the unmet clinical need 
Oncotarget2www.impactjournals.com/oncotarget
for the identification of biomarkers that can accurately 
distinguish between indolent and aggressive tumors and 
would also help form the basis for the development of 
novel therapeutic targets. 
Epigenetic changes, including DNA methylation, 
have been shown to play a role in prostate carcinogenesis 
by regulating gene expression. DNA methylation occurs 
when a methyl group is added to a cytosine base that 
precedes a guanine (CpG). This epigenetic change has 
been shown to play a role in promoting chromosomal 
stability and regulating gene expression [5, 6]. Aberrant 
DNA methylation patterns are the most widely studied 
epigenetic mechanism and have been shown to be valuable 
diagnostic [7-9], prognostic [10, 11], and predictive [12, 
13] biomarkers for PCa and other cancers [14, 15]. We, 
and others have previously identified HOXD3, TGFβ2, 
APC, and TBX15 as markers of PCa progression [16-20]. 
The integrated analyses, described in this 
manuscript, provide a comprehensive approach to 
identify potential novel candidate genes and signaling 
pathways that are regulated by epigenetic mechanisms 
and contribute to PCa progression. We compared genome 
wide methylation levels before and after treatment with 
the demethylating agent 5-Aza 2’ –deoxycytidine (DAC) 
to identify regions of CpG methylation in the PCa cell 
lines 22Rv1 and DU-145. We identified genes regulated 
by methylation mechanisms by determining differential 
gene expression post-DAC treatment in the same 
cells. Gene set enrichment analysis (GSEA) identified 
biological pathways that are over represented in these 
gene sets, including DNA replication and activation of 
ataxia telangiectasia and Rad3 related (ATR) in response 
to stress. Furthermore, we determined the prognostic 
significance of these markers by examining methylation 
levels in three independent cohorts of patients; two 
independent PCa patient cohorts with Gleason score 
(GS) 8 vs. GS6 tumors recruited at the University Health 
Network (UHN) and a third publically available dataset 
of PCa patients from The Cancer Genome Atlas (TCGA) 
database. These analyses identified novel potential 
methylation biomarkers associated with PCa progression.
RESULTS
Identification of methylated CpG probes in 
prostate cancer cell lines
We treated two cell lines with the demethylating 
agent 5-Aza 2’–deoxycytidine (DAC). 22Rv1 is derived 
from a PCa xenograft and is AR positive; while DU-145 
is derived from PCa brain metastases and is AR negative. 
Global methylation status was analyzed by performing 
methylation-sensitive restriction enzyme based differential 
methylation hybridization strategy followed by genome-
wide CpG methylation profiling. The Agilent Human 
CpG Island Microarray assessed genome-wide, 27,800 
CpG islands with 237,220 probes in or within 95bp of 
CpG islands. The hypomethylated genomic DNA (gDNA) 
fractions were isolated and we compared CpG methylation 
status before and after treatment with DAC. In the 22Rv1 
cells, we identified 11,212 CpG probes (representing 
4922 genes; p<0.05) with reduced methylation post-DAC 
treatment, suggesting these probes were methylated in the 
untreated cells. We observed 25% identified CpG probes 
were found in promoter regions while 69% probes were 
intronic and 6% were located in intergenic regions (Figure 
1). A representative list of 25 such methylated CpGs in 
22Rv1 cells is shown in Table 2. The most significant 
hypomethylated region identified after DAC treatment 
was an intragenic region of tumor protein D52 (TPD52; 
p<0.001). 
We performed a parallel analysis with DU-145 
cells and found 32,511 CpG probes (8008 genes; p<0.05) 
showed reduced methylation after treatment with DAC. 
22% identified CpG probes were found in promoter 
regions while 72% probes were located intragenically and 
6% were in intergenic regions (Figure 1). This pattern of 
differentially methylated CpG distribution throughout the 
genome is similar to the pattern observed in the 22Rv1 
cells. A representative list of CpG probes identified with 
reduced methylation after DAC treatment in DU-145 cells 
is shown in Table 3. The top significant hypomethylated 
region identified after treatment was located in an 
intragenic region of the contactin associated protein-
like 5 (CNTNAP5) gene. Other genes identified include 
Table 1: Primer and probes sequences for MethyLight analysis.
Gene Forward Primer Reverse Primer Probe
ACTA1 5’-GGATTTTTTAGTGGG GTTTCGCG-3’
5’-CCAAAAACCTAAAAACA 
TCTCC TACCG-3’
5’-AGGTCGAGAAGAGAATTTTTGGTC 
GTCGTTTTGGTAG-3’
B4GALNT1 5’-GTTTTGTAGGGGTGA AGCG -3’
5’-AATTACCTCCAAACGAA 
CCTAA -3’
5’-AGGTATCGGAGCGTAGATTTTGATT 
TTTTCGGGT-3’
ALU-C4
5’-GGTTAGGTATAGTGG 
TTTATATTTGTAATTT 
TAGTA-3’
5’-ATTAACTAAACTAATCTT 
AAACTCCTA ACCTCA-3’
5’-CCTACCTTAACCTCCC-3’
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glutathione S-transferase pi 1 (GSTP1), whose methylation 
in PCa is well documented in the literature, and homeobox 
D3 (HOXD3), T-box 15 (TBX15), and cytochrome P450, 
family 26, subfamily A, polypeptide 1 (CYP26A1), which 
we have previously shown to be methylated in PCa [21]. 
In addition, we examined the common CpG regions 
that showed decreased methylation after DAC treatment in 
both the 22Rv1 and DU-145 cell lines. These genes may 
represent common pathways in PCa that are regulated 
by methylation mechanisms. We found there were 7406 
CpG probes, representing 3380 unique genes that showed 
decreased methylation in both 22Rv1 and DU-145 cell 
lines after DAC treatment. Pathway analyses showed that 
these genes belong to pathways involved in the regulation 
of DNA methylation and histone modifications as well 
as the regulation of cell-cell adhesion and epithelial 
to mesenchymal transition, among others, which are 
important for tumorigenesis. 
Differential mRNA expression after DAC 
treatment
 In order to investigate the contribution of DNA 
methylation to the regulation of gene expression in 
PCa, we treated cells with DAC and performed mRNA 
expression profiling. Gene expression was compared 
before and after treatment and was assayed using a 
custom microarray (GEO platform accession GPL16604), 
enriched for PCa metastasis-associated genes. We 
found 6598 probes (representing 2581 genes; FDR 
p<0.05) showed increased expression in 22Rv1 cells 
treated with DAC when compared to the untreated cells, 
suggesting expression of these genes may be, in part, 
regulated by methylation mechanisms. We also found 
there were 4604 probes (2020 genes; FDR p<0.05) that 
showed decreased expression in the treated cells. This 
may be due to either off target or indirect effects (e.g. 
demethylating a repressive factor, thereby increasing its 
expression and the repression of downstream targets). We 
Table 2: A representative list of CpG sites that showed significant increased hypomethylation in 22Rv1 cells after 
treatment with 5-Aza 2’ –deoxycitidine (DAC).
Gene Symbol Gene Name CpG Location p value
TPD52 tumor protein D52 Intragenic 3.88E-07
CDR2L cerebellar degeneration-related protein 2-like Intragenic 1.50E-03
GPER1 G Protein-Coupled Estrogen Receptor 1 Promoter 2.00E-03
CLK2 CDC-like kinase 2 Intragenic 3.40E-03
ADAM8 ADAM metallopeptidase domain 8 Promoter 6.90E-03
SSTR1 somatostatin receptor 1 Intragenic 9.50E-03
OSR1 odd-skipped related 1 Intragenic 1.05E-02
BANK1 B-cell scaffold protein with ankyrin repeats 1 Promoter 1.08E-02
ACTA1 actin, Alpha 1, Skeletal Muscle Intragenic 1.18E-02
INPP5A inositol polyphosphate-5-phosphatase, 40kDa Intragenic 1.78E-02
CYP26A1 cytochrome P450, family 26, subfamily A, polypeptide 1 Promoter 2.08E-02
ADRA1A adrenoceptor alpha 1A Promoter 2.26E-02
TFDP1 transcription factor Dp-1 Intragenic 2.28E-02
RAB11B RAB11B, member RAS oncogene family 1 Intragenic 2.36E-02
OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF Intragenic 2.95E-02
NCOR2 nuclear receptor corepressor 2 Intragenic 2.99E-02
TLX1 T-cell leukemia homeobox 1 Intragenic 3.10E-02
SCAND1 SCAN domain containing 1 Promoter 3.38E-02
KCND2 potassium voltage-gated channel, Shal-related subfamily,member 2 Intragenic 3.64E-02
DHRS12 dehydrogenase/reductase (SDR family) member 12 Promoter 4.19E-02
ONECUT2 one cut homeobox 2 Intragenic 4.43E-02
B4GALNT1 beta-1,4-N-Acetyl-Galactosaminyl Transferase 1 Intragenic 4.47E-02
CD248 CD248 molecule, endosialin Intergenic 4.48E-02
HSF4 heat shock transcription factor 4 Promoter 4.55E-02
IRX3 iroquois homeobox 3 Promoter 4.61E-02
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Table 3: A representative list of CpG sites that showed significant increased hypomethylation in DU-145 
cells after treatment with 5-Aza 2’ –deoxycitidine (DAC). 
Gene Symbol Gene Name CpG Location p value
CNTNAP5 contactin associated protein-like 5 Intragenic 4.74E-06
KIAA0415 adaptor-related protein complex 5, zeta 1 subunit Intragenic 1.00E-04
SOGA2 SOGA Family Member 2 Intragenic 7.00E-04
ZNF418 zinc finger protein 418 Intragenic 1.70E-03
TBX15 T-box 15 Intragenic 1.80E-03
B4GALNT1 Beta-1,4-N-Acetyl-Galactosaminyl Transferase 1 Intragenic 1.90E-03
CENPM centromere protein M Promoter 3.30E-03
FIGN fidgetin Promoter 3.30E-03
ARRDC2 arrestin domain containing 2 Promoter 3.30E-03
OBSCN obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF Intragenic 3.50E-03
HOXD3 homeobox D3 Intragenic 3.70E-03
MMP17 matrix metallopeptidase 17 (membrane-inserted) Intragenic 5.30E-03
CRB2 crumbs homolog 2 (Drosophila) Intragenic 5.90E-03
MARK3 MAP/microtubule affinity-regulating kinase 3 Intragenic 1.71E-02
CYP26A1 cytochrome P450, family 26, subfamily A, polypeptide 1 Intragenic 2.23E-02
GSTP1 glutathione S-transferase pi 1 Intragenic 2.66E-02
PDZD4 PDZ domain containing 4 Intragenic 3.12E-02
KLK12 kallikrein-related peptidase 12 Intragenic 3.19E-02
IRX2 iroquois homeobox 2 Intragenic 3.31E-02
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) Intragenic 3.37E-02
MEX3B mex-3 RNA binding family member B Intragenic 3.48E-02
GPR135 G protein-coupled receptor 135 Intragenic 3.49E-02
COL9A3 collagen, type IX, alpha 3 Intragenic 3.99E-02
MAST1 microtubule associated serine/threonine kinase 1 Intragenic 4.57E-02
ACTA1 actin, Alpha 1, Skeletal Muscle Promoter 4.88E-02
Figure 1: Bar graph showing the distribution of the location of CpG probes that were identified in the hypomethylated 
DNA fraction after treatment with 5-Aza 2’–deoxycitidine (DAC). In the 22Rv1 cells, we identified 11,212 probes with reduced 
methylation, representing 4922 genes (p<0.05) post-DAC treatment. In the DU-145 cells, we identified 32,511 CpG probes (representing 
8008 genes, p<0.05) that showed reduced methylation after treatment. Interestingly, both cell lines showed similar distribution patterns of 
CpG locations. In the 22Rv1 cells, 25% CpG probes were found in promoter regions while 69% probes were located intragenically and 6% 
were located in intergenic regions. In the DU-145 cells, 22% CpG probes were found in promoter regions while 72% probes were located 
intragenically and 6% were located in intergenic regions. 
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performed GSEA pathway enrichment analysis to identify 
significant biological processes over represented in the 
22Rv1 cells post-DAC treatment. We found that genes 
differentially regulated post-DAC treatment were most 
significantly enriched for DNA replication, activation of 
ATR in response to replication stress, and DNA metabolic 
pathways (Figure 2A). 
We also analyzed gene expression in DU-145 cells 
after treatment with DAC and identified 16,092 probes 
(representing 5851 genes, FDR p<0.05) that showed 
significantly increased expression in treated cells when 
compared to untreated cells. There were also 12,970 
probes (4067 genes; FDR p<0.05) that showed decreased 
expression. GSEA analyses of significantly differentially 
expressed genes in DU-145 cells post-DAC identified the 
most significant pathways including microtubule motor 
activity, lysosome pathway, activation of ATR in response 
to replication stress, and fatty acid oxidation (Figure 2B). 
Correlation between reduced methylation and 
increased mRNA expression 
In order to determine genes controlled by DNA 
methylation-dependent mechanisms, we correlated 
regions of CpG hypermethylation in untreated cells with 
increased gene expression after treatment. We found 670 
genes, representing 1641 CpG probes in the 22Rv1 cell 
line had increased gene expression (adjusted p<0.05) after 
DAC treatment. This represents a total of 13% (670/4922) 
genes that had decreased methylation following DAC 
treatment. Pathway analysis showed that these genes were 
involved in cell migration and the regulation of DNA 
methyltransferase activity. 
In the DU-145 cells, we found there were 2330 
genes with decreased CpG methylation post DAC 
treatment, with a corresponding increased mRNA 
expression (adjusted p<0.05) and these were represented 
by 9910 CpG probes. This represents a total of 28% 
(2330/8008) genes that had decreased methylation 
following DAC treatment. Pathway analysis showed that 
these genes were involved in the regulation of cell-cell 
adhesion and focal adhesion assembly as well as cellular 
proliferation and migration. 
Identification of potential methylation markers in 
tumor tissues
In order to assess the potential role of these genes 
in the initiation and/or progression of PCa, we assayed 
methylation status in PCa tumors using CpG island 
Table 5: Genes identified through analysis with DU-145 cells that showed significant increased methylation in 
Gleason score 8 vs Gleason score 6 prostate cancer tumors
Gene Symbol Gene Name CpG Location Fold Change p-value
ACTA1 actin, alpha 1, skeletal muscle Intragenic 3.026 0.0007
TBX3 T-box 3 Intergenic 2.939 0.0016
HOXD3 homeobox D3 Intragenic 2.124 0.0026
VAX1 ventral anterior homeobox 1 Intragenic 3.679 0.0051
TBX15 T-box 15 Intragenic 3.155 0.0102
HOXD8 homeobox D8 Promoter 2.043 0.0124
HOXB6 homeobox B6 Intragenic 2.165 0.0174
FOXD2 forkhead box D2 Promoter 2.030 0.0243
Table 4: Genes identified through analysis with 22Rv1 cells that showed significant increased 
methylation in Gleason score 8 vs Gleason score 6 prostate cancer tumors 
Gene Symbol Gene Name CpG Location Fold Change p- value
NRIP3 nuclear receptor interacting protein 3 Promoter 2.023 <0.001
B4GALNT1 beta-1,4-N-acetyl-galactosaminyl transferase 1 Intragenic 2.19 <0.001
ACTA1 actin, alpha 1, skeletal muscle Intragenic 3.026 0.0007
TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) Intragenic 2.219 0.0039
TGFB2 transforming growth factor, beta 2 Intragenic 1.846 0.0048
TBX2 T-box 2 Intragenic 1.558 0.0121
TESC tescalcin Intragenic 1.545 0.0191
TRAF3 TNF receptor-associated factor 3 Intragenic 1.804 0.0205
DSC3 desmocollin 3 Intragenic 1.508 0.0481
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microarray analysis in 20 PCa tumors, 10 cases with 
Gleason Scores (GS) 6 (3+3) and 10 cases with GS8 
(4+4). We assessed methylation status of the 670 genes 
(1641 CpG probes) that were hypermethylated in 22Rv1 
and transcriptionally upregulated after DAC treatment. 
Among these genes, 117 genes (represented by 170 
probes) showed significant (p<0.05) increased methylation 
in GS8 compared to GS6 tumors. Nine genes, representing 
potential biomarkers for PCa, are shown in Table 4. Of 
these nine probes, eight were intragenic while one was 
located in the promoter region. A number of these genes 
have been previously shown to be methylated in PCa, 
including transforming growth factor beta 2 (TGFB2), 
transcription factor AP-2 beta (TFAP2B), T-box 2 (TBX2), 
tescalcin (TESC), and desmocollin 3 (DSC3). We also 
identified novel potential methylation markers for PCa 
including actin, alpha 1, skeletal muscle (ACTA1), beta-
1,4-N-acetyl-galactosaminyl transferase 1 (B4GALNT1), 
nuclear receptor interacting protein 3 (NRIP3), and TNF 
receptor-associated factor 3 (TRAF3). 
We performed a similar analysis with genes 
identified in the DU-145 cells. We identified 835 genes 
(1456 probes) that showed reduced methylation and 
increased gene expression post-DAC treatment in cells 
and had significant differential methylation in GS8 vs. 
GS6 PCa patients (p<0.05). Eight genes representing 
potential biomarkers are shown in Table 5. Interestingly, 
this analysis identified and confirmed a few genes that we 
previously reported to be associated with aggressive PCa 
including homeobox D3 (HOXD3), T-box 15 (TBX15), 
and T-box-3 (TBX3), as well as genes formerly reported 
methylated in PCa including homeobox D8 (HOXD8) and 
ventral anterior homeobox 1 (VAX1). Furthermore, we 
identified genes that have not been previously reported to 
be methylated in PCa including homeobox B6 (HOXB6), 
forkhead box D2 (FOXD2) and actin, alpha 1, skeletal 
muscle (ACTA1). 
We validated the correlation of methylation status 
with Gleason grade using an independent publically 
available database. Clincopathological and survival 
data for 127 PCa patients is shown in Supplementary 
Table 1. We accessed Level 3 methylation data from The 
Cancer Genome Atlas (TCGA) database, as described 
in the Materials section, and correlated with Gleason 
score. We found actin, alpha 1, skeletal muscle (ACTA1) 
had significantly higher methylation in GS ≥8 vs. GS7 
patients (p=0.035; Table 6). Also, we found homeobox 
D3 (HOXD3) showed higher methylation levels in GS≥8 
vs. GS≤6 tumors (p=0.025) while higher methylation 
levels of beta-1,4-N-acetyl-galactosaminyl transferase 1 
(B4GALNT1) were associated with GS ≥8 vs. GS7 patients 
(p=0.027). 
We experimentally verified increased methylation 
Table 6: Association of gene methylation status with Gleason Score 
Clinical χ2 p-value
Characteristic ACTA1 HOXD3 B4GALNT1
Gleason Score
    ≥8 vs. ≤6 0.258 0.025 0.205
     ≥8 vs. 7 0.035 0.113 0.027
Figure 2: Enriched gene sets identified in (A) 22Rv1 
and (B) DU-145 cells for upregulated genes following 
DAC treatment (positive normalized enrichment score 
(NES)) and downregulated genes post-DAC treatment 
(negative NES). Gene sets were found to be over-represented 
using GSEA software, with FDR (q-val) <0.05. 
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of ACTA1 and B4GALNT1 in higher Gleason grade 
tumors in a separate, independent cohort of patients. We 
measured methylation levels using the MethyLight assay, 
on an independent cohort of 10 cases of GS≥8 vs. 10 
cases of GS≤6 specimens. We found that ACTA1 showed 
significantly higher percent methylated reference (PMR) 
values in GS≥8 cases (average PMR=5.27) vs. GS≤6 cases 
(average PMR=1.44; p=0.040, Figure 3), which confirmed 
our previous results. In addition, we found B4GALNT1 
higher PMR values in GS≥8 tumors (average PMR=8.23) 
vs GS≤6 cases (average PMR= 3.11; p=0.005, Figure 3), 
again, confirming our previous results. 
DISCUSSION
In this study, we preformed comparative assessment 
of methylation and gene expression data from PCa cell 
lines after treatment with the demethylating agent DAC 
to identify genes that are potentially regulated by DNA 
methylation dependent mechanisms in PCa. These data 
provide further insight to the contribution of methylation 
mechanisms to PCa tumorigenesis. We further explored 
the role of these genes in PCa carcinogenesis by 
performing GSEA analysis and determined the biological 
pathways that are affected by DNA methylation in these 
cells. Genes regulated by methylation mechanisms also 
represent potential biomarkers for PCa patients. We 
validated potential biomarkers using publically available 
databases and experimentally using two separate cohorts 
of patients. 
In order to identify regions of CpG methylation 
in PCa cells, we employed a restriction enzyme based 
differential methylation hybridization strategy that 
enriched for hypomethylated gDNA [22]. This approach 
differs from others that focused mainly on the enrichment 
and detection of hypermethylated DNA [23-26]. Although 
focusing on the hypermethylated fraction is very useful for 
detecting major epigenetic changes in some regions of the 
genome, the overall proportion of interrogated CpG probes 
is substantially lower compared to approaches that focus 
on the unmethylated DNA fraction [22]. In addition, since 
we treated cells with a demethylating agent, we reasoned 
that quantifying methylation based on the hypomethylated 
fraction would be more logical to gain further insights into 
the genome-wide methylation events. Interestingly, we 
found that even though DU-145 cells had approximately 
three times more probes with reduced methylation post-
DAC treatment than 22Rv1 cells (32,511 vs. 11,212, 
Figure 1), the locational distribution of the CpG probes 
was very similar. Approximately 23% CpG probes were 
found in promoter regions while approximately 71% CpG 
probes were intragenic, in both cell lines. This implies a 
conserved function for CpG methylation outside promoter 
regions. The significance of gene body DNA methylation 
is not well understood. CpG islands in intragenic or 
intergenic regions have been shown to exhibit high tissue-
specific DNA methylation [27]. Recently, Maunakea et al., 
[28] showed DNA methylation in gene bodies has a role 
in regulating cell context-specific alternative promoters. 
More specifically, they examined the human SHANK3 
locus and its mouse homologue and demonstrated that 
this tissue-specific DNA methylation regulates intragenic 
promoter activity in vitro and in vivo. Moreover, intragenic 
DNA methylation has been shown to have an effect on 
chromatin structure [29] gene expression [30, 31], and 
transcriptional elongation [29, 32].
Our integrated analysis identified genes regulated by 
methylation in PCa cell lines. We examined methylation 
levels of these genes in PCa patient tumors and found 
a number of genes showed significantly differential 
methylation levels in GS8 vs. GS6 tumors, suggesting 
potential prognostic significance. We identified increased 
methylation in genes that have been previously reported, 
including, HOXD3, TBX15, DSC3 and TGFB2 in GS8 
vs. GS6 tumors (p<0.01; Table 4 and Table 5) [16, 21, 
Figure 3: Bar graph showing differential methylation levels in GS≥8 vs. GS≤6 prostate tumor specimens. ACTA1 showed 
significantly higher percent methylated reference (PMR) values in GS≥8 cases (average PMR=5.27) vs. GS≤6 cases (average PMR=1.44). 
B4GALNT1 had higher PMR values in GS≥8 tumors (average PMR=8.23) vs GS≤6 cases (average PMR= 3.11). *;p=0.040, **; p=0.005.
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33-35]. In addition, we identified a number of genes that 
have not been implicated in PCa previously. ACTA1 was 
shown to have increased methylation in GS8 vs GS6 
tumors using genome wide methylation profiling (p<0.05; 
Table 4 and 5), in GS≥8 vs. GS7 tumors using the TCGA 
database (p=0.035, Table 6), and as well as an independent 
set of GS≥8 vs. GS≤6 tumors (p<0.05, Figure 3). ACTA1 
is developmentally regulated and one study showed that 
its promoter methylation was suppressed in mice that 
were exposed to a diet with high amounts of nutritional 
phytoestrogens compared to control mice [36]. To the best 
of our knowledge, this is the only report in the literature 
examining ACTA1 methylation in cancer. In addition, 
we examined B4GALNT1 methylation levels and found 
higher methylation was associated with higher Gleason 
grade in the three independent patient cohorts examined; 
the TCGA publically available database (p=0.027, Table 
6), and two experimentally verified patient tumor cohorts 
(p<0.001, Table 4; p<0.005, Figure 3). The B4GALNT1 
gene codes for GalNAc-T, a glycosyltransferase, that is 
involved in the first step of the biosynthesis of all complex 
derivatives of asialo, a-, b- and c-series gangliosides. 
Increased mRNA expression of B4GALNT1 was observed 
after DAC treatment in colorectal cancer [37] yet this is 
the first report describing the association of B4GALNT1 
methylation with PCa progression. These markers should 
be validated in independent patient populations. 
Methylation-based testing that would allow for the 
accurate prediction of disease aggressiveness at the time 
of prostate biopsy would greatly benefit patients. Patients 
who have aggressive disease would be treated with radical 
prostatectomy, while patients predicted to have indolent 
disease would be treated with a less aggressive course 
of treatment, such as active surveillance, and would 
not have to needlessly endure the harsh side effects of 
radical prostatectomy. Epigenetic testing, by measuring 
increased methylation levels of three genes, GSTP1, 
APC and RASSF1, has been shown to accurately predict 
the presence of PCa in a negative biopsy (ConfirmMDx, 
MDxHealth, Irvine, CA, USA). Our study provides 
potential candidate genes for a methylation-based test for 
PCa aggressiveness. These candidate genes require large-
scale validation.
This study provides a comprehensive analysis 
through combined methylation and gene expression 
data from cell lines and methylation data from tumor 
specimens with different Gleason scores to help gain a 
better understanding of the epigenetic mechanisms that 
contribute to PCa tumorigenesis. Our analysis identified 
many novel genes and interesting pathways that were 
dysregulated in PCa cell lines after treatment with the 
demethylating agent, which warrant a further in-depth 
analysis. These genes also represent potential prognostic 
markers for PCa patients and provide the foundation to 
a better understanding of the molecular mechanisms 
involved in PCa. 
MATERIALS AND METHODS
Cell Lines and Treatment 
The human cell lines DU-145 (ATCC# HTB-81) and 
22Rv1 (ATCC# CRL-2505) were cultured in RPMI 1640 
media supplemented with 10% fetal bovine serum. Cells 
were maintained in humidified atmosphere with 5% CO2 
at 37°C. DNA was extracted after harvesting the cells by 
trypsinization using the QIAamp DNA Mini Kit (Qiagen). 
Total RNA was extracted using Trizol (Invitrogen) as 
recommended by the manufacturer. 
For treatment with 5-Aza 2’–deoxycitidine (DAC), 
DU-145 and 22Rv1 cells were plated in 6 cm dishes and 
incubated in culture medium with 2 μg/mL DAC for 4 
days with medium change every 2 days. Since DAC is 
incorporated into the DNA of dividing cells and inhibits 
DNA methylation by forming covalent complexes with 
DNA methyltransferases, it was important to treat the 
cells at least over their doubling time. To ensure maximum 
demethylation, we treated the cells over two doubling 
times. The doubling time for DU-145 and 22Rv1 cells 
is 29 hrs and 40 hrs, respectively. Cells were harvested 
and genomic DNA and RNA were extracted as described 
above.
Patient Samples 
We used two separate cohorts of patient tissues. The 
first patient cohort consisted of twenty fresh frozen PCa 
tissue samples [10 Gleason score (GS) 6 (3+3) and 10 GS 
8 (4+4)] and were obtained from prostatectomy specimens 
of patients with prostate cancer (PCa) diagnosed between 
2001 and 2007 at the University Health Network (UHN), 
Toronto. PCa specimens were subjected to histological 
examination by an expert pathologist (TVDK) to confirm 
tumor. The second patient cohort consisted of twenty 
formalin fixed paraffin embedded (FFPE) PCa tissue 
samples [10 Gleason score (GS) ≤6 and 10 GS 8≥] were 
obtained from prostatectomy specimens of patients with 
prostate cancer diagnosed between 2007 and 2011 at the 
UHN, Toronto. PCa specimens were reviewed by a GU 
pathologist (TVDK) to confirm Gleason grade. For both 
cohorts, patients who had therapy prior to surgery were 
not included in this study. All patients consented to the 
donation of removed tissue to the UHN tissue bank and 
samples were obtained according to protocols approved by 
the Research Ethics Boards of Mount Sinai Hospital and 
UHN, Toronto, ON. 
DNA was collected and extracted as previously 
described [38]. Briefly, consecutive serial sections (10 
micron each) were obtained from FFPE tissues and air-
dried onto slides. Areas enriched in tumor cells (>80% 
neoplastic cellularity) representing each Gleason grade 
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were marked on the slide and were manually micro 
dissected. Tissues were digested in 30μL proteinase 
K at 56°C overnight, followed by the addition of 20μL 
proteinase K and digestion for one hour at 56°C the 
following day. The recommended protocol for extraction 
of DNA from FFPE tissue using the QIAmp DNA mini 
kit (Qiagen) was then followed. DNA concentration was 
determined using the NanoDrop 2000 (Thermo Scientific, 
Wilmington, USA) and stored at 4°C.
Differential Methylation Profiling and CpG Island 
Microarray
We assayed for genome wide CpG island 
methylation in cell lines and tumor tissues using 
methylation array profiling strategy. Methylation status 
in 22Rv1 and DU-145 prostate cancer cell lines was 
determined by using differential methylation hybridization 
approach whereby the hypomethylated fraction was 
enriched pre (or prior to) and post-DAC treatment. The 
hypomethylated fraction was isolated by first digesting 
genomic DNA with the methylation-sensitive restriction 
enzymes HpaII and BstUI [22]. The cleaved ends were 
ligated with linkers, followed by further digestion with 
the restriction enzyme McrBc which cleaves DNA 
containing methylcytosine on one or both strands and will 
not digest unmethylated/hypomethylated DNA. Linker 
PCR reactions were then performed to generate the final 
target amplicons for microarray hybridization. Only the 
final hypomethylated amplicons were purified using the 
QIAquick PCR purification kit (Qiagen). We compared the 
hybridization patterns before and after DAC treatment in 
each cell line. Experiments were performed in triplicate. 
Differential methylation status was determined by 
comparing the hypomethylated fraction before and after 
DAC treatment. Genes that showed higher signal in the 
hypomethylated fraction post-DAC were considered. Any 
probes that were not associated with a gene were removed. 
Probes were considered significant if p<0.05 and retained 
for further analysis. 
CpG methylation status was assessed in tumor 
tissues by first performing differential methylation 
hybridization and selecting for the hypermethylated 
fraction as described previously [38]. Briefly, genomic 
DNA was digested with MseI. The cleaved ends were 
ligated with annealed H-12/H-24 linkers, followed by 
further digestion with two successive rounds of digestion 
with methylation-sensitive enzymes, HpaII and BstUI. 
Linker PCR reactions were then performed with pre-
treated DNA to generate the final target amplicons 
for microarray hybridization. Final hypermethylated 
amplicons were purified using the QIAquick PCR 
purification kit (Qiagen). The reference sample consisted 
of DNA isolated from lymphocytes of six healthy men age-
matched with PCa patients (GEO accession # GSE15298 ). 
Reference samples were similarly treated for final target 
generation and pooled amplicons were co-hybridized to 
the test cases for individual arrays. Methylation status was 
determined as described previously [38].
Microarray gene expression profiling and data 
analysis
Gene expression was assayed by microarray 
profiling performed on a custom Agilent 4×180 k oligo 
custom array [39] using triplicates of each of DAC-treated 
and non-treated cells. The custom microarray incorporates 
Agilent human gene expression protein-coding probes 
as well as non-coding probes, with the probes targeting 
exonic regions, 3′UTRs, 5′UTRs, as well as intronic and 
intergenic regions. After RNA isolation was performed 
(RNeasy Mini Kit, Qiagen) samples were analyzed by a 
Bioanalyzer (Agilent) to en sure high quality and integrity 
of RNA samples. 200ng of RNA from each sample was 
amplified and labeled according to the protocol for One-
Color Microarray-Based Gene Expression Analysis (Low 
Input Quick Amp Labeling Kit, Agilent). The input RNA 
was reversed transcribed into cDNA, using an oligo-
dT-promoter primer, which introduces a T7 promoter 
region. The subsequent in vitro transcription uses a T7 
RNA polymerase, which simultaneously amplifies target 
material and incorporates cyanine 3-labeled CTP. cDNA 
synthesis was performed at 40°C for 2 h, respectively. 
The labeled cRNA was purified with RNEasy Mini spin 
columns (Qiagen) and quantified using a Nanodrop-1000. 
1650 ng cRNA from each sample were loaded onto 4×180 
k custom microarray (GEO platform accession GPL16604) 
and allowed to hybridize at 65°C for 17 h. The arrays were 
scanned with the Agilent Microarray Scanner G2565CA.
Microarray data were processed with Agilent 
Feature Extraction Software (v10.7.3.1). A quantile 
between array normalization was applied and differential 
expression was determined using a Bayesian adjusted 
t-statistic from a Linear Models for Microarray Data 
(LIMMA) linear model. Gene expression was considered 
significant if fold change was >1.25 and p <0.05 (adjusted 
for a false discovery rate of 5%).
Gene Set Enrichment Analysis (GSEA)
Pathway enrichment analyses were performed on 
22Rv1 and DU-145 cell line expression array datasets 
(DAC treated) to determine pathways or biological 
processes over-represented in genes with increased or 
decreased expression following DAC treatment. Two gene 
lists were generated for pathway enrichment analyses by 
identifying unique genes within each expression dataset 
(treated 22Rv1 and DU145 cells). Genes were pre-ranked 
according to the p-value and fold-change associated 
with differential expression [-log(p-value)*SIGN(fold-
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change)]. Genes with p-value less than 0.001 were 
assigned equal ranking. Further, in cases where distinct 
genes indicated multiple significant probes, the greatest 
absolute value was taken. The software used for pathways 
enrichment analysis was Gene Set Enrichment Analysis 
(GSEA) [40, 41]. Each gene list was uploaded into GSEA 
and the program was run with 1000 gene set permutations 
to calculate false discovery rate using multiple hypothesis 
testing. Downloaded gene sets [http://download.baderlab.
org/EM_Genesets/September_14_2013/Human/symbol/] 
were used to discover over-represented pathways. 
GSEA enrichment results were shown using normalized 
enrichment scores (NES), which is a value assigned to 
each gene set after normalization across all analysed gene 
sets. NES is calculated by the following formula: NES 
= actual ES/mean (ESs against all permutations of the 
dataset), and is recommended as the primary statistic to 
examine GSEA results.
Prognostic significance and statistical analyses
In order to assess the prognostic ability of 
methylated genes, we queried the cBio Cancer Genomics 
Portal (www.cbioportal.org/publicportal/) and The Cancer 
Genome Atlas (TCGA) database for methylation data in 
prostate adenocarcinoma patients. Methylation β-values 
for identified genes of 248 patients with primary PCa using 
‘Level 3’ methylation data [normalized gene expression 
data derived from the Cancer Genome Characterization 
Center (CGCC) at the University of North Carolina (unc.
edu) using the Illumina Infinium Human Methylation 450 
platform] were accessed. Clinical information and survival 
data were obtained from The Cancer Genome Atlas 
(TCGA), available through the cBio Cancer Genomics 
Portal (www.cbioportal.org/publicportal/). Clinical data 
was available for 124 patients (Supplementary Table 1). 
We correlated methylation levels with Gleason score using 
the Chi-squared test. 
MethyLight Analysis
DNA methylation analysis was performed on PCa 
tumor specimens recruited from UHN using the semi-
quantitative MethyLight assay [42]. Briefly, 20ng of 
bisulfite-converted genomic DNA was amplified using 
locus specific PCR primers flanking an oligonucleotide 
probe with a 5’ fluorescent reporter dye and a 3’ quencher 
dye. Primers and probe sequences used for the target 
genes, ACTA1 and B4GALNT1, and the reference gene, 
ALU-C4 are shown in Table 1. Methylation levels were 
assessed by the Percent Methylated Reference (PMR), 
which is calculated by dividing the target gene:Alu-C4 
ratio of a sample by the target gene:Alu-C4 ratio of 
commercially available fully methylated DNA (Millipore) 
and multiplying by 100. The Alu-C4 PCR products 
(generated from a consensus CpG-devoid region of 
the ALU repetitive element) were used as controls to 
normalize for input DNA. Samples were analyzed using 
the ABI 7500 RT-PCR thermocycler [43]. Cycling 
conditions were as follows; 95°C for 10 minutes, followed 
by 50 cycles of 95°C for 15 sec and 60°C for 1 minute. 
Samples were analyzed in duplicate. 
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